Medical Affairs, and MSLs have traditionally been the only individuals within a life science company who can engage in discussions about the off-label uses of a product. This role has, however been challenged by the Caronia, Amarin and Pacira decisions that question whether only Medical Affairs can provide such information. In light of the court decisions companies have questioned whether Medical Affairs may, in the future, be combined with the sales force to effectively become “super sales reps”. This would, however, be a mistake.